CRNX Crinetics Pharmaceuticals (CRNX) Q4 FY25 earnings call
Crinetics Pharmaceuticals reported a strong Q4 FY25, marked by the successful commercial launch of PALSONIFY for acromegaly, demonstrating early prescriber uptake and favorable payer access. The company also advanced its late-stage pipeline with atumelnant studies in CAH and Cushing's disease, and initiated a Phase I/II study for CRN09682. With a robust cash position, the focus is on building a sustainable endocrinology business and expanding its innovative therapeutic portfolio.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
CRNX operating KPIs by quarter
| KPI | This call Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Change vs prior quarter |
|---|---|---|---|
| Enrollment forms received | 200+As we previously shared, in Q4, we received more than 200 enrollment forms.Source: earnings call transcript | 232As Scott mentioned, in the first quarter alone, we secured 232 new patient enrollment forms.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.